Sales of Gilead’s COVID-19 drug top $800 million

Gilead Sciences Inc. late Thursday swung to profit and reported rising sales thanks to its COVID-19 drug, but a revenue drop from two of its HIV drugs and ongoing concerns about the pandemic dragged the stock lower.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.